HRV Pharma is expanding its focus on peptides and high-potency oncology APIs, committing around ₹150 crore towards dedicated manufacturing capacity while continuing to operate through an asset-light model. The move reflects a focus on specialised segments where technical capabilities, regulatory readiness and reliable supply are particularly important.
Dedicated Peptide Manufacturing Capacity
Around ₹50 crore of the investment is being directed towards a dedicated peptide facility in partnership with Arene Lifesciences. The facility will cover commercial-stage as well as new-to-generic synthetic peptides across multiple therapeutic areas. HRV will retain the regulatory assets, product intellectual property and global commercialisation rights, while Arene will own the manufacturing facility and provide dedicated capacity for HRV’s requirements.
High-Potency Oncology API Facility
A further ₹100 crore is being planned for a manufacturing facility focused on high-potency oncology APIs. HRV is also setting up a majority-owned joint venture for an OEL Level 4 and 5 facility designed to handle highly toxic compounds. These investments are aimed at addressing what the company sees as a gap in the market for reliable suppliers of specialised molecules and high-potency products.
An Asset-Light Approach to Manufacturing
The strategy also represents a different way of approaching manufacturing. Instead of starting with available factory capacity and then looking for products to fill it, HRV works with customers to identify the right products first and then selects the appropriate manufacturing partner. This allows the company to retain control over product IP and regulatory assets while using specialised external infrastructure. With the peptide business expected to contribute from FY2028, the company is positioning these capabilities around segments where demand, technical complexity and supply reliability are expected to remain important.
Read the full story in Mint.
